Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

4 Aug 2005 09:43

Torex Retail PLC04 August 2005 Torex Retail plc4 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding XN Checkout Shares The Board of Torex Retail plc ("Torex Retail") announces that the offer (the"Offer") made by Evolution Securities Limited on behalf of Torex Retail for XNCheckout Holdings PLC ("XN Checkout") has today become wholly unconditional. As at 1.00 p.m. on 3 August 2005, valid acceptances had been received in respectof 26,884,727 XN Checkout Shares (representing approximately 96.03 per cent. ofXN Checkout's issued share capital). Accordingly, Torex Retail will shortly be issuing notices under s.429 CompaniesAct 1985 to XN Checkout Shareholders who have not yet accepted the Offer that itnow intends to exercise its rights to acquire compulsorily all those XN CheckoutShares still outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice. Notice will also be sent to the Board of XN Checkout requesting that the XNCheckout Directors make an application to AiM for cancellation of the admissionof XN Checkout Shares to trading on AiM. XN Checkout Shareholders who have not yet accepted the Offer should, if theyhold their XN Checkout Shares in Certificated Form, despatch their Forms ofAcceptance as soon as possible or, if they hold their XN Checkout Shares inUncertificated Form accept the Offer electronically through CREST. XN CheckoutShareholders who are in any doubt as to the procedures for acceptance shouldcontact Capita Registrars by telephone on 0870 162 3121 or if calling fromoutside the United Kingdom on +44 208 639 2157. Settlement of consideration to which any XN Checkout Shareholder is entitledwill be effected: (i) in the case of acceptances received (complete in allrespects) by 4 August 2005 within 14 days of this date; or (ii) in the case ofacceptances received (complete in all respects) after 4 August 2005 but whilethe Offer remains open, within 14 days of such receipt. Terms defined in the Offer document dated 8 July 2005 shall, unless the contextrequires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
18th Jul 20222:42 pmRNSHolding(s) in Company
18th Jul 20221:33 pmRNSHolding(s) in Company
15th Jul 20225:29 pmRNSHolding(s) in Company
27th Jun 20226:04 pmRNSHolding(s) in Company
27th Jun 202212:58 pmRNSHolding(s) in Company
16th Jun 20221:27 pmRNSExercise of Options and Total Voting Rights
28th Apr 20227:00 amRNSOrthoPure®XT clinical results presentation
26th Apr 20224:19 pmRNSResult of AGM
20th Apr 20224:26 pmRNSDirector/PDMR Shareholding
19th Apr 20227:15 amEQSHardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
8th Apr 20227:00 amRNSGrant of share options
6th Apr 20222:59 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSFinal year results for the year ended 31 Dec 2021
9th Mar 20227:00 amRNSDistribution agreement for OrthoPure® XT
2nd Mar 20227:00 amRNSNotice of Results
10th Feb 20223:45 pmRNSAdditional Director Disclosures
27th Jan 20227:00 amRNSFull Year Trading update
23rd Dec 20217:00 amRNSDirector/PDMR Shareholding
21st Dec 20212:06 pmRNSSecond Price Monitoring Extn
21st Dec 20212:01 pmRNSPrice Monitoring Extension
19th Oct 20211:15 pmEQSHardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery
8th Oct 20217:00 amRNSHolding(s) in Company
5th Oct 20214:44 pmRNSHolding(s) in Company
28th Sep 20217:00 amRNSHolding(s) in Company
24th Sep 20212:05 pmRNSDirector/PDMR Shareholding
9th Sep 20214:35 pmRNSDirector/PDMR Shareholding
8th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSLaunch of DermaPure® Meshed and VNEWTM
1st Sep 20217:00 amRNSNotice of Results
16th Aug 20217:00 amRNSHolding(s) in Company
14th Jul 20213:15 pmEQSHardman & Co Research: Q&A with Dr Martin Hall on Tissue Regenix Group Plc: New capacity now on stream
30th Jun 202111:56 amEQSHardman & Co Research: Tissue Regenix (TRX): Poised for growth
29th Jun 20211:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.